ArticlePloS one2026
Identification of common genes and biomarkers between Dermatomyositis and rheumatoid arthritis through integrated bioinformatics.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDermatomyositis (DM) and rheumatoid arthritis (RA) share immuno-inflammatory features, yet mechanisms underlying their comorbidity remain unclear. We aimed to define shared molecular mechanisms across gene regulatory networks and the immune microenvironment using integrated multi-omics and machine-learning analyses.
methodsMicroarray datasets for RA (GSE55235, GSE55457, GSE12021) and DM were retrieved from GEO. RA datasets were merged and batch-corrected with ComBat. Differentially expressed genes (DEGs) were identified using limma; key modules were derived by weighted gene co-expression network analysis (WGCNA). Intersected DEGs-module genes underwent GO/KEGG enrichment. Core genes were prioritised by LASSO regression and random-forest modelling and evaluated in external cohorts. Immune landscape was estimated with CIBERSORT and immune subpopulations profiled by single-sample GSEA. Single-cell RNA-seq (GSE159117) mapped cell-type-specific expression of core genes and inferred ligand-receptor networks.
resultsWe identified 780 DEGs in RA and 739 in DM. Intersecting DEGs with WGCNA modules yielded 47 candidates enriched for IL-17, Toll-like receptor and chemokine signalling (all P < 0.05). Four core genes (JUNB, NRGN, HCP5, RARRES3) were prioritised; HCP5 and RARRES3 showed significant differential expression and diagnostic performance in external datasets (AUC 0.634-0.846). CIBERSORT indicated enrichment of activated CD4+ memory T cells and a shift in macrophage polarisation with increased M2 signatures in both diseases. Core genes were dynamically associated with M1/M2 polarisation and T-cell subpopulations (P < 0.05). Single-cell analysis localised core gene expression to NK cells, monocytes and T/B cells, and highlighted inflammatory ligand-receptor interactions.
conclusionsIntegrative, ML-assisted transcriptomics reveals convergent RA-DM programmes centred on IL-17, TLR and chemokine pathways with remodelling of the immune microenvironment. HCP5 and RARRES3 emerge as reproducible, externally supported candidates with diagnostic potential and plausible links to macrophage polarisation and T-cell states. These findings nominate testable biomarkers and pathways for validation and provide a rationale for pathway-guided, cross-disease studies of RA-DM comorbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.